To summarize the current understanding of clinical assessment, pathophysiology, and treatment of pain in neuropathies, focusing on selected entities in which the understanding of the mechanisms underlying pain has advanced recently.
Introduction
Pain caused by peripheral neuropathies is a major health problem, particularly in individuals with diabetes, but also in patients with inflammatory neuropathies, those undergoing chemotherapy, and in many others. It is still unclear why neuropathies of apparently equal aetiology can be painful or painless. Prototypes of painful polyneuropathies are those with the prominent involvement of small unmyelinated fibres (C-fibres), such as the amyloid neuropathies and Fabry disease. However, neuropathies with nonselective fibre loss such as the alcoholic, dysproteinaemic, and some toxic neuropathies can be equally painful, as well as some neuropathies with selective large fibre loss. This review will summarize recent findings on the pathophysiology of pain in various types of neuropathies. The treatment of neuropathic pain is presently guided by experience and evidence from clinical trials. An improved understanding of the particular mechanisms leading to pain in these diseases is expected to give rise to improved and more selective treatment strategies.
The phenomenology of pain in neuropathies
The typical clinical picture in painful neuropathies is a combination of the loss of sensation, positive sensory phenomena like paraesthesias and evoked pain, and spontaneous pain (Table 1) . Major efforts are being made to describe and classify the symptoms of painful neuropathies better, motivated by the hypothesis that the individual symptoms may indicate particular pathomechanisms that in turn may point to a specific treatment strategy [1, 2, 3 . . ,4]. In a recent study of 81 patients with diabetic and non-diabetic painful neuropathy [5 . . ], deep aching pain was the most prominent symptom, not the superficial burning or paroxysmal pain traditionally regarded as most typical of neuropathic pain. The need for standardized assessment is obvious; questioning about symptoms differs widely between studies and case series, and the few available scales for the assessment of neuropathic pain have not found a major distribution [6, 7] . Evaluation schemes and standardized scales are presently being developed to assess neuropathic pain more uniformly [3 . . ,8]. The information gained by detailed assessment of individual symptoms has already partly been used in clinical drug trials, such that in these the effectiveness of a particular drug on either burning pain, paroxysmal stabbing pain or deep tissue pain can be determined [9, 10] .
Pathophysiology of pain in neuropathies
Since neuropathic pain can be due to diverse aetiologies, concepts on neuropathic pain in general may not be valid in specific neuropathies, some of which will therefore be described separately.
General concepts on neuropathic pain
Most of the current knowledge on the mechanisms of neuropathic pain is based on animal models of acute nerve injury or on in-vitro models. For up-to-date reviews of these findings see Dworkin . Although a wealth of data has emerged from the nerve injury models, it is unclear to what extent they relate to polyneuropathies in humans, which are of variable aetiologies and mostly have a slowly progressive course. A large number of distinct cellular changes that are triggered by nerve injury have been identified, which may or may not be relevant to the development of pain. An important goal will be to find out which of these changes are essential for the pain process and which are of minor importance or are secondary events [15] . As in the acute nerve injury models, in polyneuropathies there is a coexistence of injured and adjacent uninjured nerve fibres within the same peripheral nerve. The role of injured versus uninjured fibres has recently been extensively investigated, and there is now good evidence that uninjured fibres within an injured nerve take part in the signalling of pain, exhibiting spontaneous activity ], and undergoing phenotypic shifts regarding the expression of cytokines [19] and neurotrophic factors [20] .
Diabetic neuropathies
Studies of the prevalence of diabetic neuropathy give estimates of approximately 34% of diabetic patients, and the prevalence of painful diabetic neuropathy may be 11-20% [21,22
. . ]. The cause of chronic neuropathic pain in diabetic neuropathy is still unclear [23 . ]. There are few morphological differences between patients with and without pain in distal symmetrical diabetic neuropathy. In diabetic lumbosacral radiculoplexus neuropathy, inflammatory changes seem to be the underlying cause of the deep aching radicular pain [24, 25] . An impaired glucose tolerance test in the absence of overt diabetes mellitus may be associated with a small-fibre neuropathy, which is often painful [26, 27] .
Most data on the pathogenesis of pain in diabetic neuropathy are derived from the model of streptozotocin-induced diabetes in rats. As in traumatic nerve injury [28 . . ], a dysregulation of the sodium channels in dorsal root ganglion neurons can be found in streptozotocininduced diabetes, in particular an upregulation of messenger RNA and protein for the Na v 1.3, Na v 1.6, and Na v 1.9 sodium channels, and a downregulation of Na v 1.8 mRNA [29 . ]. These changes occur between 1 and 8 weeks after the onset of allodynia to tactile stimuli. An upregulation of Na v 1.3 would be expected to increase the overall neuronal sodium channel density and to introduce a rapidly repriming current. These changes should lead to a lowered firing threshold and to higher than normal firing frequencies. The upregulation of Na v 1.6 channels would be expected to contribute to intrinsic burst activity and thus to hyperexcitablity of the neurons. Furthermore, impaired potassium conductances in myelinated fibres may contribute to increased excitability [30] . In fact, in a study using mechanical stimulation and single-fibre recording [31 . ], Ad-and Abfibres had lower activation thresholds and augmented responses to von Frey hairs. Increased spontaneous activity was also found in C-fibres in a skin-nerve preparation from diabetic rats [32 . ]. Neurogenic inflammation, as measured by basal and capsaicin-induced calcitonin gene-related peptide release from the skin, is increased in diabetic rats compared with controls [33], indicating an increased sensibility of C-fibres to capsaicin and related stimuli.
At the level of the spinal cord, prostaglandin E 2 levels, as measured by haemodialysis, are elevated in diabetic rats after formalin injection into the hind-paw, indicating a pathway by which increased excitability is transmitted to the central nervous system [34] . The spinothalamic tract neurons of diabetic rats display a higher spontaneous discharge activity and enlarged receptive fields, as well as lower thresholds and augmented responses to mechanical stimulation [35 . ]. Interestingly, the responses of spinothalamic tract neurons to noxious stimuli are reduced by morphine in non-diabetic but not in diabetic rats, suggesting decreased morphine sensitivity.
The calcium channel alpha 2 delta-1 subunit, which has previously been shown to play a role in allodynic responses of spinal nerve-injured rats, is also upregulated in streptozotocin-induced diabetes, but not in vincristine ], which correlated with the onset of streptozotocin-induced hyperalgesia. The intrathecal administration of a selective mitogen-activated protein kinase/ERK inhibitor dose-dependently blocked allodynia in this model. Elevated glucose levels as such have also been implicated in the pathogenesis of pain in diabetic neuropathy. Recent experimental studies showed mechanical hyperalgesia induced by a local increase in glucose concentration at the sciatic nerve or the respective dorsal root ganglia [38] . In a small group of type I diabetic patients, pain ratings were not correlated with individual blood glucose levels, but the group with painful neuropathy had a greater glucose flux and possibly poorer diabetes control than the group with painless neuropathy [39] . In contrast, in a larger group of type II diabetic patients, glycaemic control was not a predictor of painful neuropathy [40] .
Chemotherapy-induced neuropathy
A mostly sensory and painful neuropathy is caused by cisplatin, oxaliplatin, and carboplatin. Vincristine, taxol, and suramin can induce a sensorimotor neuropathy with or without the involvement of the autonomic nervous system [41 . ]. Vincristine neuropathy, in particular, lends itself to the investigation of its pathophysiology, because good animal models in the mouse and rat are available. In the rat model, protein kinase A, protein kinase C and nitric oxide second messenger pathways contributed to mechanical hyperalgesia [42] . An abnormal temporal pattern of evoked afferent activity was found in C-fibres from vincristine-treated rats, which may contribute to the development of pain [43 . ]. Oxaliplatin alters sodium channel inactivation kinetics, and the sodium antagonist carbamazepine may reduce symptoms as well as prevent neurotoxicity after oxaliplatin exposure [44] . Of interest is the fact that patients with a pre-existing neuropathy, either hereditary or acquired, are particularly susceptible to chemotherapy-induced neuropathies [45] [46] [47] . The pathomechanism of this phenomenon is not yet known, but the practical consequence should be to screen patients' peripheral nerve function before initiating potentially neurotoxic chemotherapy.
Inflammatory neuropathies
Pain is a prominent feature in most of the inflammatory neuropathies such as chronic inflammatory demyelinating neuropathy, Guillain-Barré syndrome or vasculitic neuropathies, provided that the sensory system is involved. Fifteen to 50% of AIDS patients suffer from distal predominantly sensory neuropathy, which is often painful. In 36 HIV-1-infected patients with painful (n = 20) and non-painful (n = 16) sensory neuropathy investigated by quantitative thermal testing, a more pronounced impairment of C-fibre-mediated innocuous warm perception was found in patients with painful neuropathy [48 . ]. Patients with sarcoidosis may have a vasculitic neuropathy [49] , or a painful small-fibre neuropathy [50 . ]. Although the pathogenesis of the latter has not yet been elucidated, it is important to recognize this entity in a patient with sarcoidosis and pain.
In the inflammatory neuropathies, pain is thought to be induced by a combination of changes caused by axonal injury, such as the altered distribution of sodium channels and the increased release of inflammatory mediators in the vicinity of the nerve fibres. Inflammatory mediators, in particular in combination ('inflammatory soup'), have long been known to increase the excitability of nociceptors after injury [51] . The expression of proinflammatory cytokines in peripheral nerves is increased in most vasculitic neuropathies [52] , and in particular in specimens from patients in whom pain is a prominent symptom [53] . Recent studies focusing on the effect of TNF-a have shown an increased firing rate in injured but also in adjacent uninjured nerve fibres after the application of TNF [17 . ]. The induction of hyperalgesia by TNF-a is dependent on p38 mitogen-activated protein kinase, the inhibition of which also reduced behavioural signs of pain in an animal model [54 . ]. A protein kinase Adependent pathway is also involved [18 . ]. The spinal upregulation of cytokines may partly underlie morphine tolerance [55] .
Spinal and peripheral prostaglandins are involved in hyperalgesia after nerve injury [56, 57 . ], and the prostaglandin analogue carbaprostacyclin increased the ectopic activity of dorsal root ganglia and dorsal horn neurons in a model of nerve injury [58] . Prostaglandin E 2 is elevated in injured nerves and may contribute to hyperalgesia [59] . Cyclooxygenase 2 is upregulated in nerve biopsy specimens from patients with chronic inflammatory demyelinating neuropathy [60] . Cyclooxygenase 2 inhibitors also seem to reduce nerve damage in experimental autoimmune neuropathy [61] .
Another mediator released in tissue inflammation is serotonin (5-hydroxytryptamine). In the periphery, serotonin has algesic properties mainly through its action on 5-hydroxytryptamine 3 receptors. Nerve injury entails an increase in serotonin locally, and mice with lowered serotonin levels in the nerve as a result of a deficiency of the serotonin transporter do not develop thermal hyperalgesia after nerve injury [62 . ].
Current treatment of painful neuropathies
Treatment of pain in neuropathies is often unsatisfactory. However, this may not only be the result of a lack of adequate drugs. Out of 151 patients with neuropathic pain of diverse origin (55.6% diabetic neuropathies) completing a questionnaire, 72.8% complained of inadequate pain control [63] . Opioids, tricyclic antidepressants and anticonvulsants had never been tried by 41.1%, 59.6% and 72.2% of these patients, respectively. New antineuropathic analgesics (e.g. gabapentin) were being used by only 16.6% of the patients. The authors concluded that new and even conventional therapies were often not pursued in these patients, despite inadequate pain control. Similar results were obtained when the use of opioids was specifically investigated [64] .
The mainstay of the treatment of pain in neuropathies are tricyclic antidepressants and anticonvulsants. The available evidence for the efficacy of these drugs has repeatedly been reviewed, and treatment algorithms have been developed [65] [66] [67] [68] [69] . Gabapentin, initially investigated for the treatment of painful diabetic neuropathy and postherpetic neuralgia, has meanwhile proved efficacious for a variety of neuropathic pain states [10] . Among the older anticonvulsants, sodium valproate has recently proved effective in reducing neuropathic pain in patients with type 2 diabetes [70] . Opioids, formerly thought to be ineffective in neuropathic pain, have recently been found to reduce neuropathic pain in several randomized controlled trials [71, 72] .
The value of alpha-lipoic acid for pain treatment in diabetic neuropathy has been judged to be controversial in diverse trials. A recent trial again seemed to be in favour of a positive effect of intravenous alpha-lipoic acid at a dose of 600 mg per day [73] . Similar controversial findings have been found in trials with topical capsaicin. A recently published small trial again reported a positive effect [74 . ].
In a small study [75] , a single intravenous application of the non-competitive N-methyl-D-aspartate antagonist amantadine (200 mg) improved pain in diabetic neuropathy for at least one week. Another N-methyl-Daspartate antagonist, dextrometorphan, was efficient in selected patients with a painful diabetic neuropathy in a dose-related fashion [76] . A trial with the glycine antagonist GV196771 gave a negative result [77] . L-Acetylcarnitine is a drug that reduces pain in animal models of neuropathic and acute pain, probably by a central indirect cholinergic mechanism and via the upregulation of spinal mGlu2 receptors [78, 79] . In a multicentre trial, L-acetylcarnitine improved nerve conduction parameters and reduced pain in patients with diabetic neuropathy [80 . ]. A moderate effect on pain was found with isosorbide dinitrate spray, given under the rationale of an impaired nitric oxide production in diabetic nerves [81] . The role of botulinum toxin in the treatment of neuropathic pain is still unclear [82, 83] . Drug combinations have so far very rarely been tested. In two recent studies [84,85 . ], the addition of either amitriptyline or a cholecystokinin 2 antagonist to opioids did not improve the outcome.
Conclusion
A standardized assessment of patients with painful neuropathies will be the prerequisite for adequately evaluating outcomes in practice and in clinical trials. Preclinical research has provided us with a large body of knowledge on cellular changes after nerve injury. Closing the gap to clinical research will be necessary to understand their relevance for the pathophysiology of pain in neuropathies. This study exemplifies how a molecular finding can be correlated to sensitivity to an analgesic drug, and gives an example of how different molecular mechanisms can underlie the same neuropathic symptom. 
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